TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07098988: Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Sponsor: CatalYm GmbH · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 107 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07098988 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07098988 Rescue Dossier →